Chinese drug developer D&R Pharmaceuticals has partnered a group of domestic investment companies to back $45-million fund to speed up the development and commercialisation of health and biotechnologies from South Australia for the global market.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
